Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Valentis, Inc. (NasdaqNM:VLTS)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials | Reports
Recent Events
Aug 31Price hit new 52-week low ($3.35)
Aug 21Earnings Announcement
Location
863A Mitten Road
Burlingame, CA 94010
Phone: (650) 697-1900
Fax: (650) 652-1990
Email: bweintraub@valentis.com
Employees (last reported count): 113
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 5%
·Over the last 6 months:
 · 2 insider sells; 372.0K shares
  (20.2% of insider shares)
·Institutional: 19% (20% of float)
(66 institutions)
·Net Inst. Selling: 26.0K shares
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Valentis, Inc. is engaged in the field of biopharmaceutical delivery. The Company develops multiple proprietary gene delivery and gene expression systems and PEGylation technologies and applies its preclinical and early clinical development expertise to create novel therapeutics and improved versions of currently marketed biopharmaceuticals. Valentis has what it believes to be the broadest array of technologies and intellectual property for the delivery of biopharmaceuticals including genes, proteins, peptides, peptidomimetics, antibodies and replicating and non-replicating viruses. Valentis focuses on research, preclinical development and early-stage clinical development of products in several therapeutic areas including cardiovascular disorders, oncology, hematology and immunology. The Company's delivery systems for biopharmaceuticals are based on two broad technology platforms: gene medicines and PEGylation technologies.
More from Market Guide: Expanded Business Description

Financial Summary
Valentis develops novel therapeutics using its proprietary technologies, including multiple gene delivery and gene expression systems and PEGylation technologies designed to improve the safety, efficacy and dosing characteristics of genes, proteins and viruses. For the nine months ended 3/31/01, revenues fell 30% to $3.2 million. Net loss applicable to Common fell 22% to $29.1 million. Results reflect lower amounts from Roche, offset by the absence of R&D charges.

Recent Earnings Announcement
For the 3 months ended 06/30/2001, revenues were 1,476; after tax earnings were -10,415. (Preliminary; reported in thousands of dollars.)

More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Benjamin McGraw III, 51
Chairman, Pres, CEO
$356K--  
Bennet Weintraub, 46
CFO and VP, Fin.
203K--  
J. Tyler Martin, M.D., 41
VP, Clinical Devel. and Regulatory Affairs
--  --  
Margaret Snowden, 41
VP, Intellectual Property and Legal Affairs
151K$37K
Alain Rolland, Ph.D., 40
VP-R&D
217K--  
Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:VLTSAs of 31-Aug-2001
Price and Volume
52-Week Low
on 31-Aug-2001
$3.35 
Recent Price$4.10 
52-Week High
on 8-Nov-2000
$10.938
Beta0.40 
Daily Volume (3-month avg)64.8K
Daily Volume (10-day avg)54.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change-61.4%
52-Week Change
relative to S&P500
-48.2%
Share-Related Items
Market Capitalization$121.7M
Shares Outstanding29.7M
Float28.2M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq*)$0.85 
Earnings (ttm)-$1.38 
Earnings (mrq)-$0.39 
Sales (ttm)$0.16 
Cash (mrq*)$1.31 
Valuation Ratios
Price/Book (mrq*)4.79 
Price/EarningsN/A 
Price/Sales (ttm)25.39 
Income Statements
Sales (ttm)$4.65M
EBITDA (ttm*)-$33.7M
Income available to common (ttm)-$39.5M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsJune 30
Most recent quarter
(fully updated)
31-Mar-2001
Most recent quarter
(flash earnings)
30-June-2001
Management Effectiveness
Return on Assets (ttm)-63.38%
Return on Equity (ttm)-112.75%
Financial Strength
Current Ratio (mrq*)3.56 
Debt/Equity (mrq*)0.14 
Total Cash (mrq)$35.8M
Short Interest
As of 8-Aug-2001
Shares Short461.0K
Percent of Float1.6%
Shares Short
(Prior Month)
496.0K
Short Ratio8.09 
Daily Volume57.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001, except mrq*/ttm* items as of 31-Mar-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Some event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.